文献速递其他结缔组织病

西罗莫司治疗包涵体肌炎:随机双盲安慰剂对照2b期试验

Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial.
PubMed 文献 · Lancet Rheumatol · 2020-10-12

这项在法国巴黎单中心开展的随机双盲安慰剂对照2b期试验,纳入44例包涵体肌炎患者,比较每日口服西罗莫司2 mg与安慰剂。主要终点(12个月最大自主等长膝伸肌力相对变化)无显著差异,但部分次要终点(HAQ-DI、用力肺活量、大腿脂肪分数、6分钟步行距离)有利于西罗莫司,且不良事件较明显。

要点

  • HAQ-DI、用力肺活量、大腿脂肪分数和6分钟步行距离等次要终点有利于西罗莫司。
  • 西罗莫司组严重不良事件10例(45%),安慰剂组6例(27%);4例(18%)因不良事件停药。

核心结论

  • 基于最大自主等长膝伸肌力及其他肌力指标,未发现西罗莫司治疗包涵体肌炎有效的证据,且部分患者副作用明显。
  • 但部分次要终点显示获益证据,研究者认为足以支持开展多中心3期试验进一步评估安全性和有效性。

研究设计与样本

  • 随机、双盲、安慰剂对照、概念验证、2b期试验,在法国巴黎单家医院开展。
  • 纳入45-80岁、按既定标准确诊包涵体肌炎的男性和女性患者。
  • 合格参与者按1:1随机分配接受每日一次口服西罗莫司2 mg或安慰剂。
  • 采用计算机生成的集中平衡区组随机化(区组大小为4),未进行分层。
  • 研究包括15天筛选期(第-15天至第0天)和52周治疗期(第0天至第12个月)。

主要发现

  • 2015年7月15日至2016年5月13日筛查285例患者,44例随机分配至西罗莫司(22例)或安慰剂(22例)。
  • 其他肌群肌力(握力、肘屈伸、膝屈)、IBMWCI、IBMFR和下肢肌肉脂肪分数等次要终点组间差异不显著。
  • HAQ-DI、用力肺活量、大腿脂肪分数和6分钟步行距离等次要终点显示有利于西罗莫司的显著差异。
  • 西罗莫司组22例中10例(45%)发生严重不良事件,安慰剂组22例中6例(27%);西罗莫司组4例(18%)因不良事件停药(严重口腔溃疡、无菌性肺炎、肾功能不全、下肢外周水肿),停药后缓解。

关键数值与推荐

  • 主要终点为12个月最大自主等长膝伸肌力相对基线的变化百分比。
  • 次要终点包括第6和第12个月的6分钟步行距离、握力(指屈肌)、膝屈、肘屈伸等长肌力、用力肺活量、定量核MRI测量的肌肉脂肪替代、IBMWCI、IBMFR、HAQ-DI及质谱流式T细胞亚群分析。

临床怎么用

  • 目前证据不支持西罗莫司用于包涵体肌炎常规治疗,主要终点未显示肌力获益。
  • 部分次要终点(HAQ-DI、用力肺活量、大腿脂肪分数、6分钟步行距离)提示潜在获益,但需3期试验进一步验证。
  • 使用西罗莫司需警惕严重不良事件(如口腔溃疡、无菌性肺炎、肾功能不全、外周水肿),部分患者需停药。

局限性

  • 单中心、小样本(44例)概念验证性2b期试验。
  • 主要终点未达显著差异,次要终点结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inclusion body myositis is the most frequent myositis in patients older than 50 years. Classical immunosuppressants are ineffective in treating inclusion body myositis, and to date there are no recommendations for pharmacological approaches to treatment. When used after organ transplantation, sirolimus can block the proliferation of effector T cells, while preserving T regulatory cells, and induce autophagy, all of which are processes that are impaired in inclusion body myositis. In this pilot study, we aimed to test the efficacy of sirolimus in patients with inclusion body myositis. METHODS: This randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial was done at a single hospital in Paris, France. The study included men and women (aged 45-80 years) who had a defined diagnosis of inclusion body myositis according to established criteria. Eligible participants were randomly assigned (1:1) to receive once-daily oral sirolimus 2 mg or placebo. Centralised balanced block randomisation (blocks of four) was computer generated without stratification. The study comprised a 15-day screening period (days -15 to 0) and a 52-week treatment period (day 0 to month 12). The primary endpoint was the relative percentage change from baseline to month 12 in maximal voluntary isometric knee extension strength. Secondary endpoints included the following assessments at months 6 and 12: 6-min walking distance, isometric muscle strength for hand grip (finger flexors), knee flexion and elbow flexion and extension, forced vital capacity, muscle replacement with fat measured by quantitative nuclear MRI, Inclusion Body Myositis Weakness Composite Index (IBMWCI), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Health Assessment Questionnaire without Disability Index (HAQ-DI), and analyses of T-cell subpopulations by mass cytometry. The primary analysis was done on the intention-to-treat population. The trial is registered at ClinicalTrials.gov, NCT02481453. FINDINGS: Between July 15, 2015, and May 13, 2016, we screened 285 patients, 44 of whom were randomly allocated to sirolimus (22 patients) or placebo (22 patients). We observed no difference in the primary outcome of relative percentage change from baseline to month 12 of the maximal voluntary isometric knee extension strength (median difference 3·78, 95% CI -10·61 to 17·31; p=0·85). For secondary outcomes, differences between the groups were not significant for changes in strength of other muscle groups (grip, elbow flexion and extension, or knee flexion), IBMWCI, IBMFRS, and lower limb muscle fat fraction. However, we observed significant differences in favour of sirolimus between the study groups for HAQ-DI, forced vital capacity, thigh fat fraction, and 6-min walking distance. Ten (45%) of 22 patients in the sirolimus group had a serious adverse event compared with six (27%) of 22 patients in the placebo group. Four (18%) patients in the sirolimus group stopped their treatment because of adverse events (severe mouth ulcers, aseptic pneumonia, renal insufficiency, and peripheral lower limb oedema), which resolved after treatment discontinuation. Canker sores were the most frequent side-effect and were mainly mild or moderate in ten patients. INTERPRETATION: We found no evidence for efficacy of sirolimus for treating inclusion body myositis based on maximal voluntary isometric knee extension strength and other muscle strength measures, and the side-effects of treatment were substantial for some patients. However, we believe there was enough evidence of benefit in certain secondary outcomes to pursue a multicentre phase 3 trial to further assess the safety and efficacy of sirolimus. FUNDING: Institut national de la santé et de la recherche médicale, Direction générale de l'offre de soins, and Association Française contre les Myopathies.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Benveniste O, Hogrel JY, Belin L, et al. Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial. Lancet Rheumatol. 2020. PMID: 38273639. doi:10.1016/S2665-9913(20)30280-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。